On May 17, 2022 Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference (Press release, Oncorus, MAY 17, 2022, https://investors.oncorus.com/news-releases/news-release-details/oncorus-present-hc-wainwright-global-investment-conference [SID1234614746]). The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed by visiting the Investors & Media section of Oncorus’ website at View Source A replay of the webcast will be archived on Oncorus’ site for 90 days following the event.

On May 17, 2022 Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, reported that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright Global Investment Conference (Press release, Black Diamond Therapeutics, MAY 17, 2022, View Source [SID1234614745]). The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived on the site for 90 days.

On May 17, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported that management will participate in the upcoming H.C. Wainwright Global Investment Conference, to be held virtually and in Miami Beach from May 23-26, 2022 (Press release, Spectrum Pharmaceuticals, MAY 17, 2022, View Source [SID1234614744]). A presentation will be available on the Investor Relations section of the company’s website at View Source beginning on May 24, 2022 at 7:00 a.m. ET / 4:00 a.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 17, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences (Press release, Surface Oncology, MAY 17, 2022, View Source [SID1234614743]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the UBS Global Healthcare Conference on Monday, May 23, 2022, at 2:45 p.m. ET in New York City.

A corporate presentation at the H.C. Wainwright Global Investment Conference. The prerecorded presentation will become available on-demand starting Tuesday, May 24, 2022, at 7 a.m. ET.
Archived webcasts of the fireside chat and on-demand corporate presentation will be accessible from the Events & Presentations page of the company’s website.

On May 17, 2022 Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, reported that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference (Press release, Geron, MAY 17, 2022, View Source [SID1234614742]). The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.